Libroxar (Buprenorphine, Naloxone)

Buprenorphine acts as a partial agonist at the μ‑opioid receptor, delivering enough activation to ease withdrawal without full opioid effects, and blocks κ‑receptors to reduce dysphoria. Naloxone is an opioid antagonist that is minimally absorbed when taken sublingually but becomes active if the product is injected, blocking the receptors and discouraging injection misuse.

The specific dose of Libroxar is determined by the prescribing clinician based on the individual’s opioid use history, severity of dependence, and response to therapy. Dosing regimens are tailored to each patient and should follow the prescriber’s instructions and local regulatory guidelines.

The safety of Libroxar in pregnancy and lactation has not been definitively established. Healthcare providers must weigh the potential benefits of treating opioid dependence against any possible risks to the fetus or infant, and decisions should be made on a case‑by‑case basis with specialist input.

To order Libroxar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Libroxar combines buprenorphine with naloxone, offering partial opioid agonism while deterring injection misuse, a profile distinct from pure agonists like methadone. Compared with buprenorphine‑only products, the naloxone component adds an abuse‑deterrent safeguard, making Libroxar a preferred option in settings where injection misuse is a concern.

Libroxar should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children and unauthorized personnel.

Libroxar is administered sublingually. The tablet is placed under the tongue and allowed to dissolve completely without chewing or swallowing, ensuring optimal absorption of buprenorphine while minimizing naloxone uptake. Patients should follow the prescriber’s instructions regarding timing and food intake.

Serious risks include respiratory depression, especially during induction or when combined with other central nervous system depressants, severe hypotension, allergic reactions such as anaphylaxis, and rare hepatic toxicity. Patients should be monitored closely for these events, and any signs of severe side effects require immediate medical attention.

Libroxar is contraindicated in individuals with known hypersensitivity to buprenorphine, naloxone, or any formulation components, in patients receiving full opioid agonists for acute pain, and in those with severe respiratory insufficiency. Caution is also advised for patients with significant hepatic impairment or uncontrolled psychiatric conditions.